poisar

Stocks · News reference

Wedbush Maintains Neutral on Sionna Therapeutics, Raises Price Target to $6

BenzingaBenzinga Newsdesk

Wedbush analyst Laura Chico maintains Sionna Therapeutics (NASDAQ:SION) with a Neutral and raises the price target from $5 to $6.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncNa

    Sionna Therapeutics Reports Third Quarter 2026 Financial Results

    Sionna Therapeutics announced it will advance its SION-451 + SION-2222 dual combination into the AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in Q1 2027. The company reported a strong cash position of $249.8 million as of September 30, 2026, expected to fund operations into the second half of 2029. However, the company implemented a 46% workforce reduction in September 2026 to focus resources on the dual combination program and extend its operating runway.